Iovance Biotherapeutics, Inc. <IOVA.O>: Barclays raises target price to $13 from $11
IOVA•Related News
Earth Science Tech's Q1 net income, revenue rise
ETST•
Baker Hughes Company <BKR.O>: Morgan Stanley resumes coverage with overweight rating; price target $70
BKR•
SoCalGas to retire preferred shares for USD 31.14 each on Aug. 17
SRE•
Doximity shares surge after first-quarter revenue beats estimates
DOCS•
Mammoth Energy Q2 adjusted EBITDA rises 37% sequentially to $2.6 million; revenue more than doubles year over year to $26.1 million
TUSK•